Capricor Therapeutics (NASDAQ:CAPR) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04), FiscalAI reports.

Here are the key takeaways from Capricor Therapeutics’ conference call:

• Capricor said the deramiocel BLA remains under active FDA review with a PDUFA target date of August 22, 2026, and management expects labeling discussions in the near term.
• Management highlighted strong HOPE-3 results, including achievement of the primary PUL v2.0 endpoint, significant secondary endpoints, and encouraging cardiac data that they believe support deramiocel for DMD-associated cardiomyopathy.
• The company emphasized a favorable safety profile, citing more than 800 IV infusions across studies and up to five years of open-label extension data in some patients.
• Capricor announced it has filed suit against NS Pharma and Nippon Shinyaku seeking rescission of the distribution agreement and a preliminary injunction, arguing the current pricing structure would make broad reimbursement and patient access economically unworkable.
• The company said it is building commercial readiness and manufacturing capacity, with its San Diego facility already through FDA pre-license inspection and positioned for an initial launch, while also hiring key commercial leaders and preparing for possible self-distribution.

Capricor Therapeutics Trading Down 0.8%

Shares of Capricor Therapeutics stock traded down $0.24 during trading hours on Thursday, reaching $30.09. 382,577 shares of the company’s stock were exchanged, compared to its average volume of 1,279,687. The company has a 50 day moving average of $31.71 and a two-hundred day moving average of $24.03. The stock has a market cap of $1.74 billion, a P/E ratio of -12.97 and a beta of 0.48. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. B. Riley Financial increased their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.09.

Insider Transactions at Capricor Therapeutics

In other news, Director Karimah Es Sabar sold 7,529 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the sale, the director directly owned 7,529 shares of the company’s stock, valued at approximately $240,928. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. The trade was a 75.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 172,529 shares of company stock worth $5,302,440. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CAPR. Suvretta Capital Management LLC bought a new position in Capricor Therapeutics in the 4th quarter valued at about $51,533,000. Tang Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $49,062,000. RA Capital Management L.P. acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $43,516,000. Darwin Global Management Ltd. acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $23,168,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $10,188,000. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.